The AMSAT electrocardiograph(tianmu), “a detecting system for functional status of human body”, based on the theory of quantum physics and neurophysiology, assesses the health of human body from function comprehensively, making up for the deficiency in modern medicine that merely research structural aspects. It can complete a single measurement in 30 to 180 seconds, quickly assessing the functional status of various organs and systems of the human body, predicts the development trend of potential diseases and pathogenic factors, and gives advice to follow-up intervention. In addition, the matched software program has a dynamic analysis function, which tracks the health of human body so as to help doctors analyze the efficacy and optimize the treatment program. Tianmu is available to the sub-health population (currently 75% of the total population) and the sick, significantly improved people's quality of life. It can also provide accurate quantitative data for human of sub-health state, so that make it true to examine sub-health, and set a national health database through the establishment of personal health records.

Under this context, we developed this high-tech product of a new business model - AMSAT electrocardiograph, which helps to analyze the overall health of human body, give a warning on health risk, and assess physical and mental health comprehensively.

AMSAT electrocardiograph has been widely recognized since the successful launch of the market. The sales volume has been increasing month by month with annual sales income of RMB 50million and the profit of RMB 25 million, accounting for 15% of medical equipment. With increasing market recognition, the market share will get a bigger breakthrough.

This is a small device that suitable for home use. It has begun mass production and can be put on the market by the second half of 2017. Our team includes development group, test group, operation and maintenance personnel, marketing group and so on. AMSAT electrocardiograph has been applied for and obtained appearance patent.

Designed by Zhu Yuntao Co-designed by Zhao Linbin and Liu Yongliang

With the rapid development of economy, people enjoy the fruits of modern civilization, while more and more people are in sub-health status. Nowadays, people pay little attention to sub-health status as chronic diseases keep cropping up, which has seriously affected people's health. It costed a lot of social medical resources and expenses, and many people suffered from it. The State Administration of Traditional Chinese Medicine clearly put forward medical guidelines of prevention. And then promote the rapid growth of China's health industry. Therefore, under this context, we developed this high-tech product of a new business model - AMSAT electrocardiograph, which helps to analyze the overall health of human body, give a warning on health risk, and assess physical and mental health comprehensively. There are three types of AMSAT electrocardiographs of large, medium and small size, among which the large and medium-sized have been launched on the market, covering a number of large hospitals, health care clubs and obtaining good social response. This is a small device that suitable for home use. It has begun mass production and can be put on the market by the second half of 2017. Our team includes development group, test group, operation and maintenance personnel, marketing group and so on. AMSAT electrocardiograph has been applied for and obtained appearance patent.

It was first put into application in June 11, 2016, making up for the deficiency in modern medicine that merely research structural aspects.

AMSAT electrocardiograph has been widely recognized since the successful launch of the market. The sales volume has been increasing month by month with annual sales income of RMB 50million and the profit of RMB 25 million, accounting for 15% of medical equipment. With increasing market recognition, the market share will get a bigger breakthrough. As a small physical examination equipment, the portable AMSAT electrocardiographs, developed by Shandong HengGen Science and Technology Co., Ltd., benefits for expanding market influence, obtains higher market share and speeds up the company's listing pace.